• August 15, 2020 

    FDA OKs Liquid Biopsy to Identify EGFR-Positive Lung CancerBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved a liquid biopsy test (a type of biopsy that uses a blood draw instead of surgery) for detecting whether patients have EGFR mutations in their metastatic lung tumors, which could help guide treatment options.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 15, 2020 

    Pembrolizumab Provides Long-Term Benefit in Melanoma, Regardless of BRAF+ Status or Prior Targeted TherapyBookmark

    George Lundberg, MD

    Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes: 

    A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.

    Go to full article published by OncLive.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 7, 2020 

    The Central Nervous System Tumor Methylation Classifier Changes Neuro-Oncology Practice for Challenging Brain Tumor Diagnoses and Directly Impacts Patient CareBookmark

    George Lundberg, MD

    Academic research paper from Clinical Epigenetics curated by Editor in Chief George Lundberg, MD, who notes: 

    Brain tumor treatment decisions may be improved by integrating methylation-based tumor classification into the diagnosis process. Methylation refers to specific chemical features of tumor DNA that may impact how well different treatments might work.

    Go to full academic research paper from Clinical Epigenetics.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • August 7, 2020 

    Brain Tumor Liquid Biopsy Detects DNA Methylation ProfilesBookmark

    George Lundberg, MD

    Article from Clinical OMICs curated by Editor in Chief George Lundberg, MD, who notes: 

    Researchers have recently demonstrated a noninvasive way to diagnose and classify brain tumors using a blood test. This promising “liquid biopsy” method detects cell-free tumor DNA in the blood and analyzes its chemical features—specifically, its “methylation patterns”—with high sensitivity and accuracy. Such a test could help guide treatment decisions.

    Go to full article published by Clinical OMICs.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • July 11, 2020 

    Adult H3K27M-Mutant Diffuse Midline Glioma with Gliomatosis Cerebri Growth Pattern: Case Report and Review of the LiteratureBookmark

    George Lundberg, MD

    Research paper from the International Journal of Surgery Case Reports curated by Editor in Chief George Lundberg, MD, who notes: 

    We present here an open-access case report and literature review of a patient with the H2K27M-mutant variant of diffuse midline glioma.

    Go to full paper published in the International Journal of Surgery Case Reports.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 9, 2020 

    Molecularly Guided Therapy in Pancreatic Cancer: Untapped Potential and the ‘Bright Future’ AheadBookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Molecularly matched treatment for pancreatic cancer may extend life for some patients.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • February 22, 2020 

    Predicting Prognosis in GlioblastomaBookmark

    George Lundberg, MD

    Article from The Pathologist curated by Editor in Chief George Lundberg, MD, who notes: 

    Liquid biopsy shows surprising apparent prognostic value in glioblastoma multiforme (GBM).

    Go to full article published by The Pathologist.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • February 21, 2020 

    Comprehensive Molecular Testing Needed for Stage IV Lung Cancer

    With: David Spigel, MD

    A Q&A with David Spigel, MD, Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. Email: dspigel@tnonc.com Q: You are an… Read more »

  • February 11, 2020 

    Carcinoma of Unknown Primary Case Reviewed in Tumor Board SessionBookmark

    George Lundberg, MD

    Article from CAP Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.

    Go to full article published by CAP Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • January 31, 2020 

    Blood-Based Screening Test May Aid in Detecting GI CancersBookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    Early diagnosis remains a key for therapeutic success in gastrointestinal (GI) cancers. The sensitivity and specificity of these blood tests are encouraging.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.